ArticleWorld journal of nephrology2026
Role of fibroblast growth factor-23 in renal disease activity and bone density involvement in patients with lupus nephritis.
Article in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus-associated lupus nephritis (LN) represents a major contributor to disease-related morbidity. Disturbances in bone metabolism frequently coexist with LN, driven in part by persistent inflammation and impaired renal function. These factors are closely linked to decreased bone mineral density (BMD) and a heightened risk of fractures. Fibroblast growth factor-23 (FGF-23) has recently been recognized as a key regulator of mineral homeostasis and may serve as a marker reflecting both renal disease activity and skeletal involvement. Nevertheless, its precise role in LN activity and its impact on bone health remain inadequately defined.
aimTo determine the predictive value of FGF-23 in renal disease activity and bone density changes in patients with LN.
methodsA cross-sectional hospital-based study included 100 adult patients with LN. Patients were classified into active (
resultsPatients with active LN had significantly higher FGF-23 levels compared with those with inactive LN (149.44 ± 37.09 pg/mL
conclusionFGF-23 may be a promising biomarker for renal disease activity and BMD in patients with LN. Its elevation may reflect the interplay between disturbances in mineral metabolism, inflammatory processes, and renal involvement. Nevertheless, further large-scale, longitudinal studies are required to validate these observations and clarify the clinical utility of FGF-23 in patients with LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.